Research grant, Call number RFA-NS-27-007
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
National Institutes of Health
- , Add deadline: choose a calendar
- United States
- Institution applies
- Pharmacology, Neuropharmacology and
About
NINDS funding, within the NIH HEAL Initiative, for the preclinical optimisation and development of safe, effective and non-addictive small-molecule and biologic therapeutics for pain, carried through to Phase I clinical testing. The cooperative agreement has a preparatory UG3 phase of up to two years for lead optimisation (potency, selectivity, in vitro ADMET, pharmacokinetics and efficacy gaps needed before IND-enabling work) and an execution UH3 phase for development: non-GLP and IND-enabling toxicology, safety pharmacology, manufacturing of the candidate, IND assembly and submission. Projects follow annual go/no-go milestones and a target product profile, and can draw on NINDS contract resources for medicinal chemistry, ADMET and manufacturing and on the Preclinical Screening Platform for Pain. Hit screening, mechanism studies, devices, studies beyond Phase I, and opioid-sparing or mu-opioid-receptor projects are out of scope.
Topics
Eligibility
Covers: NINDS plans US$11 million in FY2027 for three awards; UG3 phase up to two years and UH3 phase up to four, five years in total.
U.S. organisations only; non-U.S. entities and non-U.S. components of U.S. organisations are not eligible.
U.S. organisations, including higher-education institutions, non-profits, for-profits and governments, apply on behalf of PD/PIs. Non-domestic (non-U.S.) entities and non-domestic components of U.S. organisations are not eligible. Applications must include go/no-go milestones, a target product profile table, activities for both phases and an intellectual-property strategy. After the 19 February 2027 due date, further due dates run in June, October and February until 20 February 2029.
Source: grants.gov